Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Targeting VPAC1 Receptors for Imaging Glioblastoma.

Tripathi SK, Kean R, Bongiorno E, Hooper DC, Jin YY, Wickstrom E, McCue PA, Thakur ML.

Mol Imaging Biol. 2019 Jun 18. doi: 10.1007/s11307-019-01388-5. [Epub ahead of print]

PMID:
31292914
2.

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.

Dylgjeri E, McNair C, Goodwin JF, Raymon HK, McCue PA, Shafi AA, Leiby BE, de Leeuw R, Kothari V, McCann JJ, Mandigo AC, Chand SN, Schiewer MJ, Brand LJ, Vasilevskaya I, Gordon N, Laufer TS, Gomella LG, Lallas CD, Trabulsi EJ, Feng FY, Filvaroff EH, Hege K, Rathkopf D, Knudsen KE.

Clin Cancer Res. 2019 Jul 2. doi: 10.1158/1078-0432.CCR-18-2207. [Epub ahead of print]

PMID:
31266833
3.

Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response.

Shafi AA, Schiewer MJ, de Leeuw R, Dylgjeri E, McCue PA, Shah N, Gomella LG, Lallas CD, Trabulsi EJ, Centenera MM, Hickey TE, Butler LM, Raj G, Tilley WD, Cukierman E, Knudsen KE.

Eur Urol Oncol. 2018 Sep;1(4):325-337. doi: 10.1016/j.euo.2018.04.019. Epub 2018 Jun 6.

PMID:
30467556
4.

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.

Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE.

Cancer Res. 2018 Oct 1;78(19):5680-5693. doi: 10.1158/0008-5472.CAN-18-1001. Epub 2018 Aug 16.

5.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13. Review.

6.

Transplant glomerulopathy.

Filippone EJ, McCue PA, Farber JL.

Mod Pathol. 2018 Feb;31(2):235-252. doi: 10.1038/modpathol.2017.123. Epub 2017 Oct 13. Review.

7.

Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer.

Adams TA, Vail PJ, Ruiz A, Mollaee M, McCue PA, Knudsen ES, Witkiewicz AK.

Mod Pathol. 2018 Feb;31(2):288-298. doi: 10.1038/modpathol.2017.126. Epub 2017 Oct 6.

8.

Detailed Analysis of Insulin Absorption Variability and the Tissue Response to Continuous Subcutaneous Insulin Infusion Catheter Implantation in Swine.

Hauzenberger JR, Hipszer BR, Loeum C, McCue PA, DeStefano M, Torjman MC, Kaner MT, Dinesen AR, Chervoneva I, Pieber TR, Joseph JI.

Diabetes Technol Ther. 2017 Nov;19(11):641-650. doi: 10.1089/dia.2017.0175. Epub 2017 Oct 5.

9.

VPAC1 Targeted 64Cu-TP3805 kit preparation and its evaluation.

Tripathi SK, Kumar P, Trabulsi EJ, Kim S, McCue PA, Intenzo C, Berger A, Gomella L, Thakur ML.

Nucl Med Biol. 2017 Aug;51:55-61. doi: 10.1016/j.nucmedbio.2017.04.007. Epub 2017 May 3.

10.

Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.

Gomella LG, Mann MJ, Cleary RC, Hubosky SG, Bagley DH, Thumar AB, McCue PA, Lallas CD, Trabulsi EJ.

Can J Urol. 2017 Feb;24(1):8620-8626.

11.

Intraoperative Frozen Section Analysis of the Pancreas: A Case Report and Review of the Literature.

Bonaroti JW, Doane S, McCue PA, Winter JM.

Case Rep Pancreat Cancer. 2016 Nov 1;2(1):71-74. doi: 10.1089/crpc.2016.0014. eCollection 2016.

12.

Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.

Inaguma S, Wang Z, Lasota J, Sarlomo-Rikala M, McCue PA, Ikeda H, Miettinen M.

Am J Surg Pathol. 2016 Aug;40(8):1133-42. doi: 10.1097/PAS.0000000000000653.

13.

Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.

Hutcheson J, Balaji U, Porembka MR, Wachsmann MB, McCue PA, Knudsen ES, Witkiewicz AK.

Clin Cancer Res. 2016 Jul 15;22(14):3606-17. doi: 10.1158/1078-0432.CCR-15-1883. Epub 2016 Feb 8.

14.

The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR.

Oncogene. 2016 May;35(19):2529-41. doi: 10.1038/onc.2015.325. Epub 2015 Sep 21.

PMID:
26387536
15.

Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.

Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD, Trabulsi EJ, Gomella L, Aplin AE, Languino L, Fatatis A, Rui H, Nevalainen MT.

Am J Pathol. 2015 Sep;185(9):2505-22. doi: 10.1016/j.ajpath.2015.04.026.

16.

Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.

Liao Z, Gu L, Vergalli J, Mariani SA, De Dominici M, Lokareddy RK, Dagvadorj A, Purushottamachar P, McCue PA, Trabulsi E, Lallas CD, Gupta S, Ellsworth E, Blackmon S, Ertel A, Fortina P, Leiby B, Xia G, Rui H, Hoang DT, Gomella LG, Cingolani G, Njar V, Pattabiraman N, Calabretta B, Nevalainen MT.

Mol Cancer Ther. 2015 Aug;14(8):1777-93. doi: 10.1158/1535-7163.MCT-14-0883. Epub 2015 May 29.

17.

Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.

Cheng H, Terai M, Kageyama K, Ozaki S, McCue PA, Sato T, Aplin AE.

Cancer Res. 2015 Jul 1;75(13):2737-48. doi: 10.1158/0008-5472.CAN-15-0370. Epub 2015 May 7.

18.

The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module.

Chen K, Wu K, Jiao X, Wang L, Ju X, Wang M, Di Sante G, Xu S, Wang Q, Li K, Sun X, Xu C, Li Z, Casimiro MC, Ertel A, Addya S, McCue PA, Lisanti MP, Wang C, Davis RJ, Mardon G, Pestell RG.

Cancer Res. 2015 May 15;75(10):1992-2004. doi: 10.1158/0008-5472.CAN-14-0611. Epub 2015 Mar 13.

19.

Sox10--a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors.

Miettinen M, McCue PA, Sarlomo-Rikala M, Biernat W, Czapiewski P, Kopczynski J, Thompson LD, Lasota J, Wang Z, Fetsch JF.

Am J Surg Pathol. 2015 Jun;39(6):826-35. doi: 10.1097/PAS.0000000000000398.

20.

Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.

Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP.

Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1038-1046. doi: 10.1016/j.ijrobp.2014.04.052. Epub 2014 Jul 8.

21.

SALL4 expression in germ cell and non-germ cell tumors: a systematic immunohistochemical study of 3215 cases.

Miettinen M, Wang Z, McCue PA, Sarlomo-Rikala M, Rys J, Biernat W, Lasota J, Lee YS.

Am J Surg Pathol. 2014 Mar;38(3):410-20. doi: 10.1097/PAS.0000000000000116.

22.

Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth.

Yoshida M, Selvan S, McCue PA, DeAngelis T, Baserga R, Fujii A, Rui H, Mastrangelo MJ, Sato T.

Pigment Cell Melanoma Res. 2014 Mar;27(2):297-308. doi: 10.1111/pcmr.12206. Epub 2014 Jan 6.

PMID:
24354797
23.

GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.

Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, Langfort R, Waloszczyk P, Biernat W, Lasota J, Wang Z.

Am J Surg Pathol. 2014 Jan;38(1):13-22. doi: 10.1097/PAS.0b013e3182a0218f.

24.

Targeting cell cycle and hormone receptor pathways in cancer.

Comstock CE, Augello MA, Goodwin JF, de Leeuw R, Schiewer MJ, Ostrander WF Jr, Burkhart RA, McClendon AK, McCue PA, Trabulsi EJ, Lallas CD, Gomella LG, Centenera MM, Brody JR, Butler LM, Tilley WD, Knudsen KE.

Oncogene. 2013 Nov 28;32(48):5481-91. doi: 10.1038/onc.2013.83. Epub 2013 May 27.

25.

Aberrant BAF57 signaling facilitates prometastatic phenotypes.

Balasubramaniam S, Comstock CE, Ertel A, Jeong KW, Stallcup MR, Addya S, McCue PA, Ostrander WF Jr, Augello MA, Knudsen KE.

Clin Cancer Res. 2013 May 15;19(10):2657-67. doi: 10.1158/1078-0432.CCR-12-3049. Epub 2013 Mar 14.

26.

Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures.

Ju X, Ertel A, Casimiro MC, Yu Z, Meng H, McCue PA, Walters R, Fortina P, Lisanti MP, Pestell RG.

Cancer Res. 2013 Jan 15;73(2):978-89. doi: 10.1158/0008-5472.CAN-12-2133. Epub 2012 Nov 30.

27.

Contrast enhanced transrectal ultrasound for the detection of prostate cancer: a randomized, double-blind trial of dutasteride pretreatment.

Halpern EJ, Gomella LG, Forsberg F, McCue PA, Trabulsi EJ.

J Urol. 2012 Nov;188(5):1739-45. doi: 10.1016/j.juro.2012.07.021. Epub 2012 Sep 19.

28.

Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis.

Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T, Zhong Z, McCue PA, Sang N, Ji JY, Kong B, Jiang J, Wang C.

Cell Cycle. 2012 Jun 15;11(12):2348-58. doi: 10.4161/cc.20811. Epub 2012 Jun 15.

29.

Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes.

Gatalica Z, Lilleberg SL, Monzon FA, Koul MS, Bridge JA, Knezetic J, Legendre B, Sharma P, McCue PA.

Hum Pathol. 2011 Dec;42(12):1979-88. doi: 10.1016/j.humpath.2011.02.026. Epub 2011 Jul 5.

PMID:
21733559
30.

Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation.

Powell MJ, Casimiro MC, Cordon-Cardo C, He X, Yeow WS, Wang C, McCue PA, McBurney MW, Pestell RG.

Cancer Res. 2011 Feb 1;71(3):964-75. doi: 10.1158/0008-5472.CAN-10-3172. Epub 2010 Dec 28.

31.

Detection of Merkel cell carcinoma polyomavirus in mucosal Merkel cell carcinoma.

Wu KN, McCue PA, Berger A, Spiegel JR, Wang ZX, Witkiewicz AK.

Int J Surg Pathol. 2010 Oct;18(5):342-6. doi: 10.1177/1066896910371638. Epub 2010 May 18.

PMID:
20484140
32.

microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling.

Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, McCue PA, Quong AA, Lisanti MP, Pestell RG.

Proc Natl Acad Sci U S A. 2010 May 4;107(18):8231-6. doi: 10.1073/pnas.1002080107. Epub 2010 Apr 20.

33.

Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor.

Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, Shields JA, Shields CL, Yamamoto A, Berd D, Mastrangelo MJ, Sullivan KL.

J Clin Oncol. 2008 Nov 20;26(33):5436-42. doi: 10.1200/JCO.2008.16.0705. Epub 2008 Oct 6.

PMID:
18838710
34.

PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.

Zhang K, Aruva MR, Shanthly N, Cardi CA, Rattan S, Patel C, Kim C, McCue PA, Wickstrom E, Thakur ML.

J Nucl Med. 2008 Jan;49(1):112-21. Epub 2007 Dec 12.

35.

Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.

Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, Palazzo J, McCue PA, Baffa R, Huebner K.

Oncogene. 2005 Feb 24;24(9):1625-33.

PMID:
15674328
36.

Granular cell tumor of the trachea in pregnancy: a case report and review of literature.

Ipakchi R, Zager WH, de Baca ME, Bloedon E, McCue PA, Zwillenberg D.

Laryngoscope. 2004 Jan;114(1):143-7. Review.

PMID:
14710011
37.

The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.

Turner BC, Ottey M, Zimonjic DB, Potoczek M, Hauck WW, Pequignot E, Keck-Waggoner CL, Sevignani C, Aldaz CM, McCue PA, Palazzo J, Huebner K, Popescu NC.

Cancer Res. 2002 Jul 15;62(14):4054-60.

38.

Contrast-enhanced US of the prostate with Sonazoid: comparison with whole-mount prostatectomy specimens in 12 patients.

Halpern EJ, McCue PA, Aksnes AK, Hagen EK, Frauscher F, Gomella LG.

Radiology. 2002 Feb;222(2):361-6.

PMID:
11818600
39.

Expression of cytokeratin 20 and CD44 protein in upper urinary tract transitional cell carcinoma: cytologic-histologic correlation.

Weaver EJ, McCue PA, Bagley DH, Kovatich AJ, Bibbo M.

Anal Quant Cytol Histol. 2001 Oct;23(5):339-44.

PMID:
11693559
40.

Genetic markers in renal cell carcinomas.

McCue PA, Gorstein F.

Hum Pathol. 2001 Oct;32(10):1027-8. Review. No abstract available.

PMID:
11679934
41.

Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer.

Gomella LG, Mastrangelo MJ, McCue PA, Maguire HC JR, Mulholland SG, Lattime EC.

J Urol. 2001 Oct;166(4):1291-5.

PMID:
11547060
42.

The tumor spectrum in FHIT-deficient mice.

Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, RĂ¼diger T, McCue PA, Croce CM, Huebner K.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10250-5. Epub 2001 Aug 21.

43.

Interaction of bladder glycoprotein GP51 with uropathogenic bacteria.

Shupp Byrne DE, Sedor JF, Soroush M, McCue PA, Mulholland SG.

J Urol. 2001 Apr;165(4):1342-6.

PMID:
11257713
44.

Phase I study of R24 in patients with metastatic melanoma including evaluation of immunologic parameters.

Maguire HC Jr, Berd D, Lattime EC, McCue PA, Kim S, Chapman PB, Mastrangelo MJ.

Cancer Biother Radiopharm. 1998 Feb;13(1):13-23.

PMID:
10850338
45.

Extramammary Paget disease is characterized by the consistent lack of estrogen and progesterone receptors but frequently expresses androgen receptor.

Diaz de Leon E, Carcangiu ML, Prieto VG, McCue PA, Burchette JL, To G, Norris BA, Kovatich AJ, Sanchez RL, Krigman HR, Gatalica Z.

Am J Clin Pathol. 2000 Apr;113(4):572-5.

PMID:
10761460
46.

Muir-Torre-like syndrome in Fhit-deficient mice.

Fong LY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, Siprashvili Z, Ottey M, Martin SE, Druck T, McCue PA, Croce CM, Huebner K.

Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4742-7.

47.

Loss of FHIT expression in transitional cell carcinoma of the urinary bladder.

Baffa R, Gomella LG, Vecchione A, Bassi P, Mimori K, Sedor J, Calviello CM, Gardiman M, Minimo C, Strup SE, McCue PA, Kovatich AJ, Pagano F, Huebner K, Croce CM.

Am J Pathol. 2000 Feb;156(2):419-24.

48.

Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival.

Capuzzi D, Santoro E, Hauck WW, Kovatich AJ, Rosato FE, Baffa R, Huebner K, McCue PA.

Cancer. 2000 Jan 1;88(1):24-34.

PMID:
10618602
49.

Loss or reduction of Fhit expression in renal neoplasias: correlation with histogenic class.

Hadaczek P, Kovatich A, Gronwald J, Lubinski J, Huebner K, McCue PA.

Hum Pathol. 1999 Nov;30(11):1276-83.

PMID:
10571505
50.

Association of IgA nephropathy with Clostridium difficile colitis.

Gaughan WJ, Hassan MH, McCue PA, Burke JF, Sharma K.

Am J Kidney Dis. 1999 Oct;34(4):e16.

PMID:
10518470

Supplemental Content

Loading ...
Support Center